Intercept Pharmaceuticals (NASDAQ: ICPT ) has gone on an unprecedented run. It nearly quadrupled on Thursday before adding another 60% on Friday, to become a two-day six-bagger. This all happened after lead drug candidate OCA had a trial halted because the drug was working so well in patients with NASH, a disease with no approved treatments and a leading cause of liver failure.
However, what goes up must come down -- at least a little.
Shares of Intercept fell about 20% today. This isn't just a story of investors who are taking a cold shower over the weekend and taking profits Monday. Potentially concerning data came out from the company's groundbreaking phase 2 trial, and Intercept's CEO threw a wet blanket on bullish investors by suggesting a partnership.
Watch as Motley Fool health-care analyst David Williamson discusses why the new data raised red flags for investors, why the CEO's comments were poorly received, and why Intercept is such a risky, but potentially incredibly rewarding, stock.
Picks for ultimate growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.